^
    2ms
    A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/recurrent Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1/2, N=121, Not yet recruiting, Shanghai AbelZeta Ltd.
    New P1/2 trial • Metastases
    |
    AZD7003
    9ms
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=48, Recruiting, Zhejiang University | N=20 --> 48
    Enrollment change
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression
    |
    Lenvima (lenvatinib) • AZD7003
    over1year
    First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGFβRIIDN CAR-T) in patients with advanced HCC (AACR 2023)
    In this FIH study, C-CAR031 is well tolerated and shows promising anti- tumor activity. Enrollment is ongoing to confirm initial results.
    Clinical • PK/PD data • IO biomarker • Metastases
    |
    GPC3 (Glypican 3) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    AZD7003